On May 31, 2023 Anocca AB reported that the company has successfully raised SEK 400 million through an equity financing round led by AMF and Mellby Gård (Press release, Anocca, MAY 31, 2023, View Source [SID1234632255]). The capital injection will be used to further develop the company’s unique process that enables discovery and manufacture of next generation cell therapies for cancer on an industrial scale. The financing also allows Anocca to progress the company’s first products into clinical trials.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The financing brings together a solid group of existing and new investors, including Mellby Gård, AMF, Michano, Swedbank Robur, Ramsbury, Nidoco and several well-known family offices and private investors.
"In recent years, we have made great progress in automating our research platform. In addition, our large-scale and precise analytical methods have allowed us to generate additional data that strengthens the first products that will enter clinical trials. The capital injection will fund the continued expansion of Anocca’s research, development, and manufacturing capabilities as well as the start of a first clinical trial which is planned to be initiated in 2024," says Reagan Jarvis, CEO of Anocca.
Anocca uses proprietary analytical methods to identify and produce a kind of immune cell, T-cells, that have the ability fight a specific tumour. These processes are unique and Anocca aims to be the first company that on an industrial scale can identify suitable targets on tumour cells and generate matching T-cell receptors (TCRs), a type of receptor that controls the activity of the immune system’s T-cells. Each active TCR identified by Anocca can be further developed into a highly specialised cancer treatment, or a "TCR-T" therapy.
"We appreciate the opportunity to invest in such an interesting and important Swedish research company as Anocca. The company operates at the forefront of cancer research and drug development, with its ability to create a broad range of therapies with high precision. They have an impressive capacity and position already today, and very interesting plans for future expansion and development. We look forward to being a part of Anocca’s future growth journey and believe that this will be an investment that will be beneficial for our pension holders, as well as for Sweden, Swedish research, and for patients that will have access to more effective treatments due to Anocca’s breakthrough solutions," says Anders Oscarsson, Head of Equities at AMF.
In recent years, cell therapies have shown enormous potential in the treatment of cancer. The cell therapies used in practice today, CAR-T, have revolutionised the treatment of some cancers but are effective in less than 10% of all tumours. Despite this, CAR-T has quickly created a multi-billion-dollar market. The next generation of cell therapies, TCR-T, unlike CAR-T, has the potential to target virtually all forms of cancers.
"Anocca’s unique process creates almost endless opportunities to generate new TCR-Ts on a continuous basis. This means that we now have the chance to establish a Swedish company as a global leader in future cancer treatments," says Hans Stråberg, Chairman of the Board of Anocca.
Anocca was founded in 2014 and currently has 100 employees. The company’s operations include both research and manufacturing and are located at former AstraZeneca facilities in Södertälje. In recent years, Anocca has focused on automating and expanding its platform to identify the right targets on tumour cells and matching TCRs, while preparing for regulatory approval of the manufacturing facility. Including the current capital raise, Anocca has received a total of SEK 1.3 billion in venture capital. In addition, in December 2022, Anocca was granted a venture debt facility from the European Investment Bank (EIB) of EUR 25 million.
Danske Bank acted as financial advisor to Anocca in the transaction.